search
Back to results

Topical r-Hirudin ( Thrombexx ) Efficacy in Treatment of Haematomas

Primary Purpose

r-Hirudin (Thrombexx) Efficacy in Treatment of Haematomas

Status
Unknown status
Phase
Phase 4
Locations
Egypt
Study Type
Interventional
Intervention
active product ( Thrombexx) assigned to arm 1
Placebo assigned to arm 2
Sponsored by
MinaPharm Pharmaceuticals
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for r-Hirudin (Thrombexx) Efficacy in Treatment of Haematomas focused on measuring Thrombexx, Topical r-Hirudin, Efficacy, haematoma

Eligibility Criteria

20 Years - 60 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age of patients between 20 and 60 years old.
  • Patients with all types of haematoma.

Exclusion Criteria:

  • Presence of infected wound requiring hospitalization or surgical intervention.
  • History of allergy or hypersensitivity to any of the ingredients.
  • Patients with coagulation disorders like haemophilia.
  • Patients who are on anticoagulants like Warfarin and Acetylsalicylic acid .
  • Patients who are taking digestive enzymes like alfa chemotrypsin.

Sites / Locations

  • Prof. Mahmoud HafezRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Arm 1 : active product (Thrombexx)

Arm 2 : Placebo

Arm Description

100 patients will have the active product(Thrombexx), their visits on days 1,4,8 and 16 for target parameters assessment

100 patients will have placebo , their visits on days 1,4,8 and 16 for target parameters assessment

Outcomes

Primary Outcome Measures

Size of haematoma
Assessment the size of haematoma will be by ruler with unit centimeter(cm) , The ruler will measure the longest 2 intersecting line.
Size of oedema
Assessment the size of oedema will be by measurement the circumference in unit centimeter(cm).
Severity of Pain
Assessment of pain severity will be by Vas score
Change in Colour
Assessment of colour will be by colour grade scale , A=Bluish red , B=Blue ,C= Faint

Secondary Outcome Measures

Full Information

First Posted
October 7, 2013
Last Updated
October 9, 2013
Sponsor
MinaPharm Pharmaceuticals
search

1. Study Identification

Unique Protocol Identification Number
NCT01960569
Brief Title
Topical r-Hirudin ( Thrombexx ) Efficacy in Treatment of Haematomas
Official Title
Single Centre,Randomized,Phase IV Study to Assess the Topical r-Hirudin (Thrombexx)Efficacy in the Patients With Haematomas
Study Type
Interventional

2. Study Status

Record Verification Date
October 2013
Overall Recruitment Status
Unknown status
Study Start Date
October 2013 (undefined)
Primary Completion Date
January 2014 (Anticipated)
Study Completion Date
April 2014 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
MinaPharm Pharmaceuticals

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Single centre ,Phase IV , interventional, The study includes : 200 patients, 100 Patients will have Topical r-Hirudin (Thrombexx) and 100 patients will have placebo . The patients will be randomized to the active product (arm 1) or to placebo (arm 2). The study consists of 4 visits as the following : Visit 1 : on day 1 to check patient eligibility and also for randomization . Visit 2 : on day 4 to assess target parameters Visit 3 : on day 8 to assess target parameters Visit 4 : on day 16 to assess target parameters
Detailed Description
Single centre ,Phase IV , interventional, The study includes : * 200 patients, 100 Patients will have Topical r-Hirudin (Thrombexx) and 100 patients will have placebo . The patients will be randomized to the active product (arm 1) or to placebo (arm 2). The study consists of 4 visits as the following : Visit 1 : on day 1 to check patient eligibility and also for randomization . Visit 2 : on day 4 to assess target parameters Visit 3 : on day 8 to assess target parameters Visit 4 : on day 16 to assess target parameters Study objective :Assessment the Efficacy of Topical r-Hirudin in treatment of haematomas ,also in resolving of the associated oedema Study duration : 6 months Selection of trial subjects: Inclusion Criteria : Age of patients between 20 and 60 years old. Patients with all types of haematomas. Exclusion Criteria: Presence of infected wound requiring hospitalization or surgical intervention. History of allergy or hypersensitivity to any of the ingredients. Patients with coagulation disorders like haemophilia. Patients who are on anticoagulants like Warfarin and Acetylsalicylic acid . Patients who are taking digestive enzymes like alfa chemotrypsin. Target parameters : 1.Size of haematoma.( Measured by ruler) , The ruler will measure the longest 2 intersecting line. 2.Size of oedema : by measurement of oedema circumference 3.Pain (by Vas score). 4.Change in colour ( by colour grade scale ) .

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
r-Hirudin (Thrombexx) Efficacy in Treatment of Haematomas
Keywords
Thrombexx, Topical r-Hirudin, Efficacy, haematoma

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
200 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Arm 1 : active product (Thrombexx)
Arm Type
Active Comparator
Arm Description
100 patients will have the active product(Thrombexx), their visits on days 1,4,8 and 16 for target parameters assessment
Arm Title
Arm 2 : Placebo
Arm Type
Placebo Comparator
Arm Description
100 patients will have placebo , their visits on days 1,4,8 and 16 for target parameters assessment
Intervention Type
Drug
Intervention Name(s)
active product ( Thrombexx) assigned to arm 1
Other Intervention Name(s)
Topical r-Hirudin
Intervention Description
Dispense 2-3 cm of cream or gel, 2-3 times per day and carry out a light massage until complete
Intervention Type
Other
Intervention Name(s)
Placebo assigned to arm 2
Primary Outcome Measure Information:
Title
Size of haematoma
Description
Assessment the size of haematoma will be by ruler with unit centimeter(cm) , The ruler will measure the longest 2 intersecting line.
Time Frame
6 months
Title
Size of oedema
Description
Assessment the size of oedema will be by measurement the circumference in unit centimeter(cm).
Time Frame
6 months
Title
Severity of Pain
Description
Assessment of pain severity will be by Vas score
Time Frame
6 months
Title
Change in Colour
Description
Assessment of colour will be by colour grade scale , A=Bluish red , B=Blue ,C= Faint
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age of patients between 20 and 60 years old. Patients with all types of haematoma. Exclusion Criteria: Presence of infected wound requiring hospitalization or surgical intervention. History of allergy or hypersensitivity to any of the ingredients. Patients with coagulation disorders like haemophilia. Patients who are on anticoagulants like Warfarin and Acetylsalicylic acid . Patients who are taking digestive enzymes like alfa chemotrypsin.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Mahmoud Hafez, Professor
Phone
002 0100 7566299
Email
mhafez@msn.com
First Name & Middle Initial & Last Name or Official Title & Degree
Moustafa Sameer, Dr
Phone
002 0100 6016 212
Email
msameer@minapharm.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mahmoud Hafez, Professor
Organizational Affiliation
6th October university
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Ahmed Moneer, Dr
Organizational Affiliation
6th october university
Official's Role
Study Chair
Facility Information:
Facility Name
Prof. Mahmoud Hafez
City
Cairo
Country
Egypt
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ahmed Moneer, Dr
Phone
002 0100 8608676
Email
dr_ahmedmoneer@yahoo.com
First Name & Middle Initial & Last Name & Degree
Mahmoud Hafez, Professor

12. IPD Sharing Statement

Citations:
PubMed Identifier
30046714
Citation
El-Mowafi H, El Araby A, Kandil Y, Zaghloul A. Randomized, double-blind, placebo-controlled, interventional phase IV investigation to assess the efficacy and safety of r-hirudin gel (1120I.U) in patients with hematomas. Res Pract Thromb Haemost. 2017 Nov 6;2(1):139-146. doi: 10.1002/rth2.12049. eCollection 2018 Jan.
Results Reference
derived

Learn more about this trial

Topical r-Hirudin ( Thrombexx ) Efficacy in Treatment of Haematomas

We'll reach out to this number within 24 hrs